

2021 4th Quarter Analyst Briefing

25 Feb 2022





Disclaimer

This presentation has been prepared by Unisem (M) Berhad ("Unisem" or the "Company") solely for use at the Company's quarterly analyst briefing held virtually on 25 Feb 2022. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The Company or any of its affiliates, advisors or representatives expressly disclaims any and all liability (whether direct or indirect, contract, tort or otherwise) for any losses or liabilities howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. The contents of this presentation may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

This presentation made by representatives of the Company includes certain statements that are not descriptions of historical facts, but are forward-looking statements. These forward-looking statements may include statements about our plans and objectives for future expansion and operations, and other statements containing forward looking terminology such as "may," "believes," "anticipates," "intends," "expects," "projects," "looking forward," "targets," "plans," or similar terms, variations of such terms or the negative of such terms. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All of such assumptions are inherently subject to uncertainties and contingencies beyond our control and upon assumptions with respect to future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectations and actual results may vary (perhaps materially) from certain of the results anticipated herein. The Company undertakes no obligation, and disclaims any obligation, to publicly update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.



Consolidated Statements of Profit or Loss (From Continuing Operations)

Sequential Quarterly Comparison

(RM Thousand except EPS)	4Q 2021	%	3Q 2021	%	Change
Revenue	426,396	100.0	366,356	100.0	16.4%
Revenue in USD '000	101,844		87,394		16.5%
Cost of Sales	352,221	82.6	307,990	84.1	14.4%
Gross Profit	74,175	17.4	58,366	15.9	27.1%
Operating profit	57,471	13.5	45,710	12.5	25.7%
Net profit	57,274	13.4	40,422	11.0	41.7%
EPS – Basic (sen)	3.55		2.51		
EBITDA	106,831	25.1	94,207	25.7	13.4%
Depreciation	49,360	11.6	48,497	13.2	1.8%
Forex (loss)/gain	(2,721)	-0.6	517	0.1	nm



Consolidated Statements of Profit or Loss (From Continuing Operations)

<u> </u>	<u> </u>	•
Corresponding	()IIOrtori	// Amnarican
COHESDOHOHE	Viuai iei iv	/
oon coponania	Qual telly	Companison

				-	-
(RM Thousand except EPS)	4Q 2021	%	4Q 2020	%	Change
Revenue	426,396	100.0	366,371	100.0	16.4%
Revenue in USD '000	101,844		89,269		14.1%
Cost of Sales	352,221	82.6	290,810	79.4	21.1%
Gross Profit	74,175	17.4	75,561	20.6	-1.8%
Operating profit	57,471	13.5	56,418	15.4	1.9%
Net profit	57,274	13.4	53,905	14.7	6.2%
EPS – Basic (sen)	3.55		3.62		
EBITDA	106,831	25.1	101,323	27.7	5.4%
Depreciation	49,360	11.6	44,905	12.3	9.9%
Forex loss	(2,721)	-0.6	(6,839)	-1.9	60.2%



Consolidated Statements of Profit or Loss (From Continuing Operations)

Corresponding 12-Month Comparison

(RM Thousand except EPS)	FY2021	%	FY 2020	%	Change
Revenue	1,568,923	100.0	1,289,294	100.0	21.7%
Revenue in USD '000	378,658		307,490		23.1%
Cost of Sales	1,297,944	82.7	1,064,099	82.5	22.0%
Gross Profit	270,979	17.3	225,195	17.5	20.3%
Operating profit	214,134	13.6	164,940	12.8	29.8%
Net profit	198,243	12.6	142,579	11.1	39.0%
EPS – Basic (sen)	12.35		9.75		
EBITDA	407,670	26.0	332,499	25.8	22.6%
Depreciation	193,536	12.3	167,558	13.0	15.5%
Forex loss	(4,000)	-0.3	(7,506)	-0.6	-46.7%



4Q 2021 Revenue & EBITDA


(From Continuing Operations)

RM Revenue : RM426.4m vs RM366.4m (16.4%)

USD revenue : USD101.8m vs USD87.4m (16.5%)

• EBITDA: RM106.8m vs RM94.2m (13.4%)

EBITDA margin : 25.1% vs 25.7 % (-2.3%)






4Q 2021 Earnings

(From Continuing Operations)

Gross Profit: RM74.2m vs RM58.4m (27.1%)

• GP margin: 17.4% vs 15.9 % (9.4%)


• Net profit: RM57.3m vs RM40.4m (41.7%)





Revenue Breakdown

Recover in Leaded packages - contribution from Ipoh plant






Revenue Breakdown

Recover in Comm segment - contribution from Ipoh plant

By Market Segments





Selective Information from Consolidated Statements of Financial Position

Net cash at end Dec 2021: RM481.0 million

(in RM Thousand)	31 Dec 2021	31 Dec 2020	Change
Property plant & equipment	1,637,477	1,215,064	34.8%
Cash and Bank Balances	655,959	664,095	-1.2%
Group term loan & bank borrowings	174,925	207,400	-15.7%
Net Assets per share (RM)	1.3428	1.1383	18.0%
Current ratio	2.43	3.17	-23.3%
Debt/equity ratio	0.08	0.12	-33.3%



Capex & Headcount

- Capex incurred in 4Q21: RM143.1m mainly to increase capacity for assembly and test in Chengdu and Ipoh
- Group Headcount was at 5,968 in end Dec 2021.
 Headcount decrease at Ipoh plant.

	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21
Capex (RMmil)	84.8	81.7	49.9	54.5	137.7	156.0	134.3	143.1
Headcount	6,810	5,966	5,892	5,738	6,135	6,144	6,074	5,968



4Q 2021 Highlight

- Utilisation rates remain high in Chengdu plant, both in wafer bumping and assembly & test. Phase 3 plant construction has started.
- Assembly & test operations in Ipoh plant & UAT were affected by headcount shortage.
- Utilisation rates at wafer bumping operations in UAT below optimal due to wafer shortage.



Thank You

"Proven Technologies, Innovative Processes"